血液系统恶性肿瘤微环境的免疫代谢重塑与治疗耐受

WALID M, SABOOR M, HAQUE S, et al. The tumor microenvironment in hematologic malignancies: immune evasion, metabolic reprogramming, and therapeutic resistance[J]. Blood Science, 2026, 8(1): e00270.

LAPLANE L, DULUC D, BIKFALVI A, et al. Beyond the tumour microenvironment[J]. International Journal of Cancer, 2019, 145(10): 2611-2618.

SIDHU I, BARWE S P, GOPALAKRISHNAPILLAI A. The extracellular matrix: a key player in the pathogenesis of hematologic malignancies[J]. Blood Reviews, 2021, 48: 100787.

LI Z W, DALTON W S. Tumor microenvironment and drug resistance in hematologic malignancies[J]. Blood Reviews, 2006, 20(6): 333-342.

CRANE G M, JEFFERY E, MORRISON S J. Adult haematopoietic stem cell niches[J]. Nature Reviews Immunology, 2017, 17(9): 573-590.

刘文慧, 吴涛. 单细胞转录组测序在多发性骨髓瘤诊治和预后中的意义[J]. 中国病理生理杂志, 2024, 40(8): 1554-1558.

GIALLONGO S, DUMINUCO A, DULCAMARE I, et al. Engagement of mesenchymal stromal cells in the remodeling of the bone marrow microenvironment in hematological cancers[J]. Biomolecules, 2023, 13(12): 1701.

汤颖俊, 郭青, 智亚琴, 等. CXCR4/STAT3在骨髓基质细胞介导的急性髓系白血病耐药中的作用研究[J]. 中华血液学杂志, 2016, 37(2): 119-123.

DING Z, SHI R, HU W, et al. Cancer-associated fibroblasts in hematologic malignancies: elucidating roles and spotlighting therapeutic targets[J]. Frontiers in Oncology, 2023, 13: 1193978.

BRENNER A K, NEPSTAD I, BRUSERUD O. Mesenchymal stem cells support survival and proliferation of primary human acute myeloid leukemia cells through heterogeneous molecular mechanisms[J]. Frontiers in Immunology, 2017, 8: 106.

何旎涵, 周文. 多发性骨髓瘤细胞与骨髓微环境互作机制研究进展[J]. 四川大学学报(医学版), 2023, 54(3): 475-481.

PASSARO D, DI TULLIO A, ABARRATEGI A, et al. Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia[J]. Cancer Cell, 2017, 32(3): 324-341.e6.

ERBA B G, GRUPPI C, CORADA M, et al. Endothelial-to-mesenchymal transition in bone marrow and spleen of primary myelofibrosis[J]. American Journal of Pathology, 2017, 187(8): 1879-1892.

SOLIMANDO A G, DI SUMMA S, VACCA A, et al. Cancer-associated angiogenesis: the endothelial cell as a checkpoint for immunological patrolling[J]. Cancers, 2020, 12(11): 3380.

KOMOHARA Y, NIINO D, OHNISHI K, et al. Role of tumor-associated macrophages in hematological malignancies[J]. Pathology International, 2015, 65(4): 170-176.

LI W, WANG F, GUO R, et al. Targeting macrophages in hematological malignancies: recent advances and future directions[J]. Journal of Hematology & Oncology, 2022, 15: 110.

侯健, 王君颖. 多发性骨髓瘤免疫微环境的研究进展[J]. 肿瘤防治研究, 2022, 49(5): 375-378.

KOWALSKA W, BOJARSKA-JUNAK A. Monocytic MDSC as a source of immunosuppressive cytokines in chronic lymphocytic leukemia microenvironment[J]. Folia Histochemica et Cytobiologica, 2020, 58(1): 25-36.

ANTUAMWINE B B, BOSNJAKOVIC R, HOFMANN-VEGA F, et al. N1 versus N2 and PMN-MDSC: a critical appraisal of current concepts on tumor-associated neutrophils and new directions for human oncology[J]. Immunological Reviews, 2023, 314(1): 250-279.

ROESSNER P M, SEIFFERT M. T-cells in chronic lymphocytic leukemia: guardians or drivers of disease?[J]. Leukemia, 2020, 34(8): 2012-2024.

USTUN C, MILLER J S, MUNN D H, et al. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?[J]. Blood, 2011, 118(19): 5084-5095.

ZHOU M, SACIRBEGOVIC F, ZHAO K, et al. T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect[J]. Nature Communications, 2020, 11(1): 4227.

郑如冰, 肖毅. 肿瘤浸润性淋巴细胞在恶性血液系统疾病中的研究进展[J]. 中华血液学杂志, 2024, 45(6): 610-614.

PACZULLA A M, ROTHFELDER K, RAFFEL S, et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion[J]. Nature, 2019, 572(7768): 254-259.

FISHER J G, DOYLE A D P, GRAHAM L V, et al. Disruption of the NKG2A:HLA-E immune checkpoint axis to enhance NK cell activation against cancer[J]. Vaccines, 2022, 10(12): 1993.

LUCIANO M, KRENN P W, HOREJS-HOECK J. The cytokine network in acute myeloid leukemia[J]. Frontiers in Immunology, 2022, 13: 1000996.

MUKAIDA N, TANABE Y, BABA T. Chemokines as a conductor of bone marrow microenvironment in chronic myeloid leukemia[J]. International Journal of Molecular Sciences, 2017, 18(8): 1824.

HAO M, ZHANG L, AN G, et al. Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells[J]. Journal of Hematology & Oncology, 2011, 4: 37.

HOELLENRIEGEL J, ZBORALSKI D, MAASCH C, et al. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization[J]. Blood, 2014, 123(7): 1032-1039.

IRIGOYEN M, GARCIA-RUIZ J C, BERRA E. The hypoxia signalling pathway in haematological malignancies[J]. Oncotarget, 2017, 8(22): 36832-36844.

BOLZONI M, CHIU M, ACCARDI F, et al. Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target[J]. Blood, 2016, 128(5): 667-679.

CHEN Z, SIMON-MOLAS H, CRETENET G, et al. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment[J]. Blood, 2022, 140(6): 630-643.

WANG H, ZHANG J, REN H, et al. Lipid metabolism in multiple myeloma: pathogenesis, therapeutic opportunities, and future directions[J]. Frontiers in Oncology, 2025, 15: 1531928.

姚嘉一, 徐子真. 免疫代谢在急性髓系白血病中的研究进展[J]. 肿瘤防治研究, 2025, 52(8): 725-730.

BECKER A, THAKUR B K, WEISS J M, et al. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis[J]. Cancer Cell, 2016, 30(6): 836-848.

MENU E, VANDERKERKEN K. Exosomes in multiple myeloma: from bench to bedside[J]. Blood, 2022, 140(23): 2429-2442.

ZANETTI C, KRAUSE D S. Caught in the net: the extracellular matrix of the bone marrow in normal hematopoiesis and leukemia[J]. Experimental Hematology, 2020, 89: 13-25.

COX T R, BIRD D, BAKER A M, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis[J]. Cancer Research, 2013, 73(6): 1721-1732.

HIDESHIMA T, MITSIADES C, TONON G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets[J]. Nature Reviews Cancer, 2007, 7(8): 585-598.

UY G L, RETTIG M P, MOTABI I H, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia[J]. Blood, 2012, 119(17): 3917-3924.

ANSELL S M. Nivolumab in the treatment of Hodgkin lymphoma[J]. Clinical Cancer Research, 2017, 23(7): 1623-1626.

ROSENBLATT J, AVIGAN D. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?[J]. Blood, 2017, 129(3): 275-279.

CAI L, LI Y, TAN J, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy[J]. Journal of Hematology & Oncology, 2023, 16(1): 101.

王跃, 刘澎. 多发性骨髓瘤抑制性免疫微环境的研究进展[J]. 中国临床医学, 2025, 32(4): 665-674.

RAFIQ S, HACKETT C S, BRENTJENS R J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy[J]. Nature Reviews Clinical Oncology, 2020, 17(3): 147-167.

MAUDE S L, LAETSCH T W, BUECHNER J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia[J]. New England Journal of Medicine, 2018, 378(5): 439-448.

NEELAPU S S, CHAVEZ J C, SEHGAL A R, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)[J]. Blood, 2024, 143(6): 496-506.

LIN Y, QIU L, USMANI S, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma[J]. Lancet Oncology, 2024, 25(8): e374-e387.

MUNSHI N C, ANDERSON L D, SHAH N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma[J]. New England Journal of Medicine, 2021, 384(8): 705-716.

黄玥, 胡永仙, 黄河. 造血干细胞移植与CAR-T细胞治疗新模式的探索与实践[J]. 临床血液学杂志, 2025, 38(9): 663-669.

YIN X, HE L, GUO Z. T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it[J]. Immunology, 2023, 169(4): 400-411.

中国医师协会血液科医师分会, 中华医学会血液学分会. 嵌合抗原受体T细胞治疗多发性骨髓瘤中国血液临床专家共识(2026年版)[J]. 中华血液学杂志, 2026, 47(4): 319-326.

中华医学会血液学分会实验诊断学组, 中华医学会血液学分会浆细胞疾病学组, 中国医师协会多发性骨髓瘤专业委员会. 基于骨髓样本的多发性骨髓瘤微小残留病检测中国专家共识(2024年版)[J]. 中华血液学杂志, 2024, 45(6): 534-541.

VOORHEES P M, MANGES R F, SONNEVELD P, et al. A phase 2 multicentre study of siltuximab in patients with relapsed or refractory multiple myeloma[J]. British Journal of Haematology, 2013, 161(3): 357-366.

中国医师协会血液科医师分会, 中华医学会血液学分会. 中国多发性骨髓瘤诊治指南(2024年修订)[J]. 中华内科杂志, 2024, 63(12): 1186-1195.

CHO B S, KIM H J, KONOPLEVA M. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside[J]. Korean Journal of Internal Medicine, 2017, 32(2): 248-257.

PETTY A J, YANG Y. Tumor-associated macrophages in hematologic malignancies: new insights and targeted therapies[J]. Cells, 2019, 8(12): 1526.

XIANG X, WANG J, LU D, et al. Targeting tumor-associated macrophages to synergize tumor immunotherapy[J]. Signal Transduction and Targeted Therapy, 2021, 6(1): 75.

吴秀英, 常进. 多发性骨髓瘤免疫微环境的研究进展[J]. 医学分子生物学杂志, 2023, 20(2): 184-188.

TABE Y, KONOPLEVA M, ANDREEFF M. Fatty acid metabolism, bone marrow adipocytes, and AML[J]. Frontiers in Oncology, 2020, 10: 155.

ZHOU X, HE R, HU W X, et al. Targeting myeloma metabolism: how abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors[J]. Neoplasia, 2024, 50: 100974.

WANG L, LIU W Q, BROUSSY S, et al. Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis[J]. Frontiers in Pharmacology, 2024, 14: 1307860.

MEDINGER M, MROSS K. Clinical trials with anti-angiogenic agents in hematological malignancies[J]. Journal of Angiogenesis Research, 2010, 2: 10.

LYSSIOTIS C A, KIMMELMAN A C. Metabolic interactions in the tumor microenvironment[J]. Trends in Cell Biology, 2017, 27(11): 863-875.

SHORT N J, KONOPLEVA M, KADIA T M, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges[J]. Cancer Discovery, 2020, 10(4): 506-525.

中华医学会血液学分会白血病淋巴瘤学组. 成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2023年版)[J]. 中华血液学杂志, 2023, 44(9): 705-712.

顾芯源, 唐文娇, 李燕, 等. 多发性骨髓瘤小鼠模型构建的研究进展[J]. 中国医学科学院学报, 2023, 45(3): 512-518.

RANA S, THOMAS L, KIRKHAM A M, et al. CAR-NK cells to treat patients with cancer: a systematic scoping review of published studies and registered clinical trials[J]. Cytotherapy, 2025, 27(10): 1179-1189.

中国临床肿瘤学会骨髓瘤专家委员会, 中国抗癌协会血液肿瘤专业委员会骨髓瘤与浆细胞疾病学组. 多发性骨髓瘤疗效评估与微小残留病监测中国指南(2024年版)[J]. 中华血液学杂志, 2024, 45(12): 1065-1070.

JIANG G, QIN Y, HUANG Z, et al. CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells[J]. Experimental Hematology & Oncology, 2025, 14